Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 72

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 72
---

of this offering.

| 42 |

Fees and Expenses

The following table shows the
per share and accompanying warrant and per pre-funded warrant and accompanying warrant and
total placement agent fees we will pay in connection with the sale of the securities in this offering.

|                      |     | Per Share and        
 Accompanying Warrant |     | Per Pre-Funded Warrant and Accompanying Warrant |
|:---------------------|:----|:---------------------|:----|:------------------------------------------------|
| Placement Agent Fees |     | $                    |     | $                                               |
| Total                |     | $                    |     | $                                               |

We have agreed to pay the placement
agent a cash fee equal to 6.5% of the gross proceeds raised at the closing of this offering. We also agreed to issue warrants to the placement
agent for the purchase of a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this
offering. In addition, we have agreed to reimburse the placement agent for its legal fees and expenses and other out-of-pocket expenses
in an amount up to $100,000. We estimate the total offering expenses of this offering that will be payable by us, excluding the placement
agent fees and expenses, will be approximately $ .

Placement Agent Warrants

In addition,
we have agreed to issue to the placement agent or its designees warrants to purchase up to
shares of common stock (which represents 4% of the aggregate number of shares of common stock issued in this offering) with an exercise
price of $ per share (representing 100% of the combined public
offering price per share of common stock (or pre-funded warrant) and accompanying warrant in this offering). The placement agent warrants
will be non-exercisable for six (6) months after the date of the closing and will expire five years after the commencement of sales of
the offering. The form of the placement agent warrants has been included as an exhibit to this registration statement of which this prospectus
is a part.

Lock-up Agreements

We and each of our officers and
directors have agreed with the placement agent to be subject to a lock-up period of 60 days following the date of closing of
the offering pursuant to this prospectus. This means that, during the applicable lock-up period, we and such persons may not offer
for sale, contract to sell, sell, distribute, grant any option, right or warrant to